glp receptor 1 agonists Glucagon-like peptide-1 (GLP-1) are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and #obesity. GLP-1 receptor agonists and GLP-1 and glucose-dependent insulinotropic GLP-1 Receptor Agonists in Solid

GLP-1RAs hold promise as dual-action agents in IBD, offering potential benefits in metabolic control, weight loss, and disease modulation through immunological and barrier-enhancing effects

This release can result in pancreatic edema, causing enzymes and other toxic substances to be trapped within the pancreas and leading to tissue damage in the pancreas and acute pancreatitis

Once-weekly semaglutide for weight management: a clinical review

Glucagon-like peptide-1 receptor agonists: A narrative review of clinical pharmacology and implications for peri-operative practice

The drugs work by mimicking GLP-1, a hormone the gut releases after eating that stimulates insulin release and suppresses glucagon to control blood sugar